Autoimmune News: Breaking Autoimmune News, Comments and Articles.

Consuming coffee linked to lower risk of detrimental liver disease, study finds

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease Week 2013 conference in Orlan...

Coffee consumption linked to reduced risk of autoimmune liver disease

Research presented today at Digestive Disease Week explores new discoveries in liver disease research, with findings about the impact of coffee on autoimmune disease and palliative care for cirrhotic patients. read more

Consuming coffee linked to lower risk of an autoimmune liver disease

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease.

Study Links Coffee to Lower Risk for Rare Liver Disease

SATURDAY, May 18 (HealthDay News) -- Just a few extra cups of coffee each month might help prevent the development of an autoimmune liver disease known as primary sclerosing cholangitis (PSC), a new study suggests. Investigators from the Mayo Clinic...

Coffee consumption associated with reduced risk of autoimmune liver disease

(Digestive Disease Week) Research presented today at Digestive Disease Week® explores new discoveries in liver disease research, with findings about the impact of coffee on autoimmune disease and palliative care for cirrhotic patients.

Consuming coffee linked to lower risk of detrimental liver disease, Mayo Clinic finds

(Mayo Clinic) Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis, an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease Week 2013 conference...

[AbbVie] pays for option to acquire [Alvine] equity or its celiac disease compound

In an effort to strengthen its existing gastroenterology pipeline, [Abbott]’s spin off [AbbVie Inc.] has paid $70mm up front for the exclusive option to acquire either equity in [Alvine Pharmaceuticals Inc.] (developing therapies autoimmune and inf...

[Ambit] gets $25.1mm through private placement concurrent with IPO close

[Ambit Biosciences Corp.] (kinase inhibitors for cancer, autoimmune, and inflammatory diseases) raised $25.1mm through the private sale of 3.1mm common shares at $8 to existing shareholders. The placement was made concurrent with the closing of Ambit...

RuiYi and Genor BioPharma collaborate on development in China of RYI-008

USA and China-based RuiYi says it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-Interleukin-6 monoclonal antibody with a unique phar...

Scientists develop potential new treatment for autoimmune diseases

Scientists at Montana State University have developed a therapeutic that has potential as a biological drug or probiotic food product to combat many of the more than 80 autoimmune disorders that affect some 23.5 million people in the United States.

Belgium's Galapagos says on track to meet 2013 guidance

BRUSSELS, May 17 (Reuters) - Galapagos, the Belgian developer of drugs to fight autoimmune diseases such as lupus and rheumatoid arthritis, said it was on track to meet its full-year revenue guidance this year.

UCSF researchers create first functioning human thymus tissue from embryonic stem cells

Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells, in the laboratory. The researchers showed that, in mice, the tissue can be used to foster the devel...

RuiYi and Genor Enter License and Collaboration for Novel mAb

RuiYi Inc., a San Diego-Shanghai biotech startup, has signed an exclusive license and collaboration with Genor BioPharma to develop RuiYi’s lead molecule in China. The drug candidate, RYI-008, is a novel anti-IL-6 monoclonal antibody with poten...

Celiac Disease Awareness Month with Joy Keys

Philadelphia, PA, May 17, 2013 --(PR.com)-- Celiac Disease Awareness Month Celiac disease is an autoimmune digestive disease that damages the villi of the small intestine and interferes with absorption of nutrients from food. Date: May 18th, 2013 Time: 11:00 a.m. - 11:30 a.m. ET Call in number: 646-929-0368 URL: http://www.blogtalkradio.com/joykeys/2013/05/18/celiac-awareness-month-with-joy-...

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease.  Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.  Upon successful c...

Pharmacy Advantage: Going Above and Beyond for Patient Assistance

Locally based Pharmacy Advantage Specialty Pharmacy takes action to innovatively bring about solutions for patients navigating prescription access. As a result of partnerships with national non-profit patient assistance foundations and drug manufacturers, the company's funding department has successfully acquired significantly over one million dollars in copayment support in 2012. Troy, MI (P...

Biogen Idec Foundation Awards $250,000 to East End House to Develop Genetics Education Program

– GenoExplorers Seeks to Introduce Middle School Students to Genetics Concepts Through Interactive Learning – Today the Biogen Idec Foundation announced a $250,000 grant to East End House to develop, implement and evaluate an interactive out-of-school-time (OST) genetics program for middle school youth in Cambridge.

LRI National Patient Coalition Advocacy Culminates in Launch of Federal Provider Education Program

NEW YORK, May 16, 2013 /PRNewswire/ --  The Lupus Research Institute (LRI) National Patient Coalition participated in today's launch of the Lupus Initiative®, the culmination of its five-year advocacy campaign resulting in $4.6 million in Federal funding to make the healthcare provider education program possible. Helping to draw attention to the need addressed by the Initiative to trai...

Neuropathy Diagnosis Obstacles Damaging to Patients' Health

For National Neuropathy Awareness Week (May 13-17), The Neuropathy Association and the Hereditary Neuropathy Foundation Call Attention to the Diagnostic Challenges Hurting Millions of Neuropathy Patients. New York, NY (PRWEB) May 16, 2013 Continued lack of peripheral neuropathy awareness combined with Medicare reimbursement cuts for diagnostic tools are causing major impediments to neuropathy epi...

Annual General Meeting of Active Biotech AB

The Annual General Meeting of Active Biotech was held on May 15, 2013. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Peter Hofvenstam, Magnhild Sandberg, Peter Sjöstrand and Peter Thelin were re-elected. Rolf Kiessling was elected as a new Bo...

TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events

BETHESDA, Md., May 16, 2013 /PRNewswire/ -- TNI BioTech, Inc.,  (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows: Dear Shareholders, The board of direct...

Ambit Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, May 16, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share.  Ambit has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 shares at the initial public offering price to cover over-allotments, if any.  Ambit's common stock is...

Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists

Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice MISSISSAUGA, ON, May 16, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced tha...

RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune d...

RuiYi, Genor to Develop Autoimmune Antidody

RYI-008 has the potential to treat autoimmune diseases and cancer